Anadis to commercialise BioGard
Thursday, 04 September, 2008
Anadis [ASX: ANX] is to begin commercialisation of BioGard, a treatment designed to maintain gastrointestinal and immune system health.
The treatment, aimed at people undergoing antiretroviral therapy for HIV/AIDS, will be marketed as medical food.
BioGard's active ingredient is a formulation of antigen-targeted Bovine Clostrum Powder (BCP). The cows from which the powder is sourced will be vaccinated with a mixture of lipopolysaccarides implicated as key drivers of AIDS pathogenesis.
It will at first be made available in tablet form, sold over-the-counter but intended for use under medical supervision.
The product's ingredients and manufacturing process has been approved by the TGA.
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
